These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 28526632)
41. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Letter. Kaplan-Marans E J Urol; 2022 Sep; 208(3):566-567. PubMed ID: 35648648 [No Abstract] [Full Text] [Related]
42. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Reply. Ory J; Ramasamy R J Urol; 2022 Sep; 208(3):567. PubMed ID: 35648647 [No Abstract] [Full Text] [Related]
43. Editorial Comment: Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy. Barros R Int Braz J Urol; 2023; 49(1):150-151. PubMed ID: 36512463 [No Abstract] [Full Text] [Related]
44. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data. Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997 [TBL] [Abstract][Full Text] [Related]
47. [Androgens and cardiovascular risk: A series of case report in the French and Canadian pharmacovigilance databases]. Rochoy M; Thomas R; Béné J; Deleplanque D; Vantyghem MC; Gautier S; Deplanque D; Prog Urol; 2018 May; 28(6):315-321. PubMed ID: 29650456 [TBL] [Abstract][Full Text] [Related]
48. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer. Meza J; Weaver K; Martin S Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582 [No Abstract] [Full Text] [Related]
50. Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Chrysant SG; Chrysant GS Hosp Pract (1995); 2018 Apr; 46(2):47-55. PubMed ID: 29478348 [TBL] [Abstract][Full Text] [Related]
51. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Swerdloff RS; Wang C Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501 [TBL] [Abstract][Full Text] [Related]
52. Current and future testosterone delivery systems for treatment of the hypogonadal male. Pfeil E; Dobs AS Expert Opin Drug Deliv; 2008 Apr; 5(4):471-81. PubMed ID: 18426387 [TBL] [Abstract][Full Text] [Related]
53. Controversies with testosterone therapy. Khera M Can J Urol; 2020 Aug; 27(S3):20-23. PubMed ID: 32875998 [TBL] [Abstract][Full Text] [Related]
54. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature. Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741 [TBL] [Abstract][Full Text] [Related]
55. Reflections on the T Trials. Swerdloff R; Wang C Andrology; 2020 Nov; 8(6):1512-1518. PubMed ID: 32902162 [TBL] [Abstract][Full Text] [Related]
56. Is testosterone a friend or a foe of the prostate? Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469 [TBL] [Abstract][Full Text] [Related]
58. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Rodriguez KM; Pastuszak AW; Khera M Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247 [TBL] [Abstract][Full Text] [Related]